Table 3 Desirability of orphan drug incentives for neglected diseases
From: Expert Delphi survey on research and development into drugs for neglected diseases
| Â | Â | % (n) | % (n) | % (n) | % (n) | % (n) | Â | Â |
|---|---|---|---|---|---|---|---|---|
| Â | Â | very desirable | desirable | undesirable | very undesirable | no judgment | Total valid % (n) | Total N (Missing) |
Market exclusivity | Round I | 7,8% (9) | 19,1% (22) | 26,1% (30) | 20,9% (24) | 26,1% (30) | 100% (115) | 159 (44) |
| Â | Round II | 3,6% (2) | 20,0% (11) | 36,4% (20) | 21,8% (12) | 18,2% (10) | 100% (55) | 77 (22) |
Tax credits | Round I | 14,2% (16) | 48,7% (55) | 6,2% (7) | 1,8% (2) | 29,2% (33) | 100% (113) | 159 (46) |
| Â | Round II | 20,4% (11) | 46,3% (25) | 11,1% (6) | 3,7% (2) | 18,5% (10) | 100% (54) | 77 (23) |
Protocol assistance | Round I | 25,9% (30) | 44,0% (51) | 4,3% (5) | 0,0% (0) | 25,9% (30) | 100% (116) | 159 (43) |
| Â | Round II | 33,9% (19) | 55,4% (31) | 3,6% (2) | 0,0% (0) | 7,1% (4) | 100% (56) | 77 (21) |
Fee reduction/Fee waivers (e.g. for marketing approval, scientific advice) | Round I | 27,0% (31) | 53,9% (62) | 3,5% (4) | 0,9% (1) | 14,8% (17) | 100% (115) | 159 (44) |
| Â | Round II | 28,1% (16) | 56,1% (32) | 7,0% (4) | 0,0% (0) | 8,8% (5) | 100% (57) | 77 (20) |